SIREN : 479811291
ALIRA HEALTH is a French company founded 21 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in PARIS (75008), this company of category PME shows in 2024 a revenue of 28.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-25
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28 681 119 € | 26 969 002 € | 24 989 249 € | 11 661 821 € | 12 428 195 € | 5 859 729 € | 4 866 737 € | 3 490 490 € | 1 296 948 € |
| Net income | -7 382 305 € | -13 711 132 € | -3 639 250 € | -2 123 137 € | 1 570 517 € | 354 860 € | 505 670 € | 618 541 € | 43 275 € |
| EBITDA | -783 356 € | -9 330 607 € | -1 609 275 € | -1 620 092 € | 2 354 100 € | 501 857 € | 706 791 € | 915 520 € | -17 366 € |
| Net margin | -25.7% | -50.8% | -14.6% | -18.2% | 12.6% | 6.1% | 10.4% | 17.7% | 3.3% |
In 2024, ALIRA HEALTH achieves revenue of 28.7 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +47.3%. Vs 2023: +6%. After deducting consumption (29 k€), gross margin stands at 28.7 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -783 k€, representing -2.7% of revenue. Positive scissor effect: EBITDA margin improves by +31.9 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -7.4 M€ (-25.7% of revenue), which will impact equity.
28 681 119 €
28 651 722 €
-783 356 €
-1 046 643 €
-7 382 305 €
-2.7%
The debt ratio (= Financial debt / Equity x 100) stands at 150%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 17%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
150.389%
16.786%
-1.068%
-69.923
4.6%
In 2024, the debt ratio of ALIRA HEALTH (150.39) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of ALIRA HEALTH (16.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of ALIRA HEALTH (-69.92) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 75.49. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
75.49
-909.859
In 2024, the liquidity ratio of ALIRA HEALTH (75.49) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of ALIRA HEALTH (-909.9x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 320 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 489 days. Excellent situation: suppliers finance 169 days of the operating cycle (retail model). Overall, WCR represents 317 days of revenue, i.e. 25.3 M€ to permanently finance. Over 2016-2024, WCR increased by +8423%, requiring additional financing.
25 277 244 €
320 j
489 j
0 j
317 j
Based on 69 transactions of similar company sales
in 2024,
the value of ALIRA HEALTH is estimated at
18 897 993 €
(range 10 998 075€ - 20 896 609€).
The price/revenue ratio is 0.66x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 69 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ALIRA HEALTH with other companies in the same sector:
Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion
The revenue of ALIRA HEALTH in 2024 is 28.7 M€.
ALIRA HEALTH recorded a net loss in 2024.
The headquarters of ALIRA HEALTH is located in PARIS (75008), in the department Paris.
The tax return of ALIRA HEALTH is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ALIRA HEALTH operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.